Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma.
Biomarker and diagnostic research for round cell liposarcoma has been reported in the published literature.
13 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and gene therapy. Pipeline includes 1 PHASE2, 10 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02275286](https://clinicaltrials.gov/study/NCT02275286) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients |
PHASE1 |
Grupo Espanol de Investigacion en Sarcomas |
RECRUITING |
[NCT05492682](https://clinicaltrials.gov/study/NCT05492682) | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | PHASE1 | Valo Therapeutics Oy | RECRUITING |
[NCT04699292](https://clinicaltrials.gov/study/NCT04699292) | International Prospective Registry on Local Treatment Approaches in MLS | — | The Netherlands Cancer Institute | RECRUITING |
[NCT07261657](https://clinicaltrials.gov/study/NCT07261657) | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | EARLY_PHASE1 | Seth Pollack | RECRUITING |
[NCT06239272](https://clinicaltrials.gov/study/NCT06239272) | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | PHASE1 | St. Jude Children's Research Hospital | RECRUITING |
116 publications have been identified in PubMed for round cell liposarcoma. Research spans Review / Meta-Analysis (29%), Case Report / Case Series (26%), and Diagnostic / Biomarker (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 34 | 29% |
Patient case studies | 30 | 26% |
Testing and diagnosis research | 14 | 12% |
Laboratory research | 12 | 10% |
Disease patterns and progression | 11 | 9% |
Clinical study results | 9 | 8% |
Other research | 4 | 3% |
New treatment approaches | 2 | 2% |
Dupont M (2026). [PMID: 41472526](https://pubmed.ncbi.nlm.nih.gov/41472526/). *Expert Rev Anticancer Ther*. [Review / Meta-Analysis]
Fathallah I (2026). [PMID: 42253670](https://pubmed.ncbi.nlm.nih.gov/42253670/). *Int J Surg Case Rep*. [Case Report / Case Series]
Liu J (2026). [PMID: 42192448](https://pubmed.ncbi.nlm.nih.gov/42192448/). *J Transl Med*. [Review / Meta-Analysis]
Lansu J (2026). [PMID: 42141895](https://pubmed.ncbi.nlm.nih.gov/42141895/). *JAMA Oncol*. [Clinical Trial Publication]
Xu J (2026). [PMID: 41560045](https://pubmed.ncbi.nlm.nih.gov/41560045/). *Medicine (Baltimore)*. [Review / Meta-Analysis]
Ruggeri S (2026). [PMID: 41171439](https://pubmed.ncbi.nlm.nih.gov/41171439/). *Skeletal Radiol*. [Diagnostic / Biomarker]
Nishio J (2026). [PMID: 41482346](https://pubmed.ncbi.nlm.nih.gov/41482346/). *Cancer Genomics Proteomics*. [Review / Meta-Analysis]
Perronne L (2026). [PMID: 42193026](https://pubmed.ncbi.nlm.nih.gov/42193026/). *Cancers (Basel)*. [Basic Science / Preclinical]
Ford J (2026). [PMID: 42240833](https://pubmed.ncbi.nlm.nih.gov/42240833/). *Pediatr Radiol*. [Diagnostic / Biomarker]
Ates KE (2026). [PMID: 42151322](https://pubmed.ncbi.nlm.nih.gov/42151322/). *Sci Rep*. [Epidemiology / Natural History]